These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29050191)

  • 21. Tafamidis (Vyndaqel): a light for FAP patients.
    Nencetti S; Rossello A; Orlandini E
    ChemMedChem; 2013 Oct; 8(10):1617-9. PubMed ID: 24000164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey.
    Durmuş-Tekçe H; Matur Z; Mert Atmaca M; Poda M; Çakar A; Hıdır Ulaş Ü; Oflazer-Serdaroğlu P; Deymeer F; Parman YG
    Neuromuscul Disord; 2016 Jul; 26(7):441-6. PubMed ID: 27238058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP).
    Ando Y
    Med Mol Morphol; 2005 Sep; 38(3):142-54. PubMed ID: 16170462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.
    Sekijima Y; Ueda M; Koike H; Misawa S; Ishii T; Ando Y
    Orphanet J Rare Dis; 2018 Jan; 13(1):6. PubMed ID: 29343286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent progress in the understanding and treatment of transthyretin amyloidosis.
    Sekijima Y
    J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Liver transplantation for familial amyloid polyneuropathy].
    Adams D; Slama M; Samuel D
    Presse Med; 2010 Jan; 39(1):17-25. PubMed ID: 19419835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hereditary transthyretin amyloidosis].
    Hund E
    Nervenarzt; 2014 Oct; 85(10):1291-7. PubMed ID: 25123367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Familial amyloid polyneuropathy].
    Yamashita T; Ando Y; Uchino M
    Brain Nerve; 2011 Jun; 63(6):583-95. PubMed ID: 21613661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of liver transplantation on the natural history of oculopathy in Portuguese patients with transthyretin (V30M) amyloidosis.
    Beirão JM; Malheiro J; Lemos C; Matos E; Beirão I; Pinho-Costa P; Torres P
    Amyloid; 2015 Mar; 22(1):31-5. PubMed ID: 25475560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transthyretin familial amyloid polyneuropathy.
    Planté-Bordeneuve V; Kerschen P
    Handb Clin Neurol; 2013; 115():643-58. PubMed ID: 23931808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Presentations of transthyretin associated familial amyloid polyneuropathy in Argentina].
    Chaves M; Bettini M; Marciano S; Sáez S; Cristiano E; Rugiero M
    Medicina (B Aires); 2016; 76(2):105-8. PubMed ID: 27135849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vitreous amyloidosis after liver transplantation in patients with familial amyloid polyneuropathy: ocular synthesis of mutant transthyretin.
    Munar-Qués M; Salva-Ladaria L; Mulet-Perera P; Solé M; López-Andreu FR; Saraiva MJ
    Amyloid; 2000 Dec; 7(4):266-9. PubMed ID: 11132095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity.
    Ikeda S; Nakazato M; Ando Y; Sobue G
    Neurology; 2002 Apr; 58(7):1001-7. PubMed ID: 11940682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers.
    Sousa MM; Ferrão J; Fernandes R; Guimarães A; Geraldes JB; Perdigoto R; Tomé L; Mota O; Negrão L; Furtado AL; Saraiva MJ
    Lab Invest; 2004 Jul; 84(7):865-73. PubMed ID: 15122304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and pathological findings in familial amyloid polyneuropathy caused by a transthyretin E61K mutation.
    Murakami T; Nishimura H; Nagai T; Hemmi S; Kutoku Y; Ohsawa Y; Sunada Y
    J Neurol Sci; 2017 Oct; 381():55-58. PubMed ID: 28991715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New therapeutic approaches for familial amyloidotic polyneuropathy (FAP).
    Ando Y
    Amyloid; 2003 Aug; 10 Suppl 1():55-66. PubMed ID: 14640043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical picture and outcome of transthyretin-related familial amyloid polyneuropathy (FAP) in Japanese patients.
    Ikeda S
    Clin Chem Lab Med; 2002 Dec; 40(12):1257-61. PubMed ID: 12553427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of familial amyloid polyneuropathy due to Phe33Val TTR with vitreous involvement as the initial manifestation.
    Kono S; Manabe Y; Tanaka T; Fujii D; Sakai Y; Narai H; Omori N; Ueda M; Ando Y; Abe K
    Intern Med; 2010; 49(12):1213-6. PubMed ID: 20558946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
    Planté-Bordeneuve V; Gorram F; Salhi H; Nordine T; Ayache SS; Le Corvoisier P; Azoulay D; Feray C; Damy T; Lefaucheur JP
    J Neurol; 2017 Feb; 264(2):268-276. PubMed ID: 27878441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unwanted road to anaemia in transthyretin familial amyloid polyneuropathy may continue irrespective of tafamidis treatment.
    Ikeda T; Masuda T; Ueda M; Yamashita T; Misumi Y; Shinriki S; Ando Y
    Ann Clin Biochem; 2018 Sep; 55(5):571-575. PubMed ID: 29310464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.